263 related articles for article (PubMed ID: 12560429)
1. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
Patt YZ; Hassan MM; Lozano RD; Brown TD; Vauthey JN; Curley SA; Ellis LM
J Clin Oncol; 2003 Feb; 21(3):421-7. PubMed ID: 12560429
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
Patt YZ; Hoque A; Lozano R; Pozdur R; Chase J; Carrasco H; Chuang V; Delpassand ES; Ellis L; Curley S; Roh M; Jones DV
J Clin Oncol; 1997 Apr; 15(4):1432-8. PubMed ID: 9193336
[TBL] [Abstract][Full Text] [Related]
3. Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study.
Vitale FV; Romeo P; Vasta F; Panebianco V; Calì S; Rotondo S; Ferraù F; La Greca M
Anticancer Res; 2007; 27(6B):4077-81. PubMed ID: 18225574
[TBL] [Abstract][Full Text] [Related]
4. Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study.
Tanaka K; Yabushita Y; Nakagawa K; Kumamoto T; Matsuo K; Taguri M; Endo I
Eur J Surg Oncol; 2013 Dec; 39(12):1364-70. PubMed ID: 24183169
[TBL] [Abstract][Full Text] [Related]
5. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Leung TW; Tang AM; Zee B; Yu SC; Lai PB; Lau WY; Johnson PJ
Cancer; 2002 Jan; 94(2):421-7. PubMed ID: 11905412
[TBL] [Abstract][Full Text] [Related]
6. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
Kuroda M; Kobayashi Y; Urawa N; Yamamoto M; Mifuji R; Araki J; Tanaka H; Horiike S; Itani T; Furjita N; Konishi M; Iwasa M; Kaito M; Adachi Y
Hepatogastroenterology; 2007 Mar; 54(74):518-21. PubMed ID: 17523311
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.
Patt YZ; Jones DV; Hoque A; Lozano R; Markowitz A; Raijman I; Lynch P; Charnsangavej C
J Clin Oncol; 1996 Aug; 14(8):2311-5. PubMed ID: 8708722
[TBL] [Abstract][Full Text] [Related]
8. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma.
Urabe T; Kaneko S; Matsushita E; Unoura M; Kobayashi K
Oncology; 1998; 55(1):39-47. PubMed ID: 9428374
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
Kasai K; Ushio A; Kasai Y; Sawara K; Miyamoto Y; Oikawa K; Kuroda H; Takikawa Y; Suzuki K
Cancer; 2012 Jul; 118(13):3302-10. PubMed ID: 22072099
[TBL] [Abstract][Full Text] [Related]
10. Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus.
Wu J; Huang WJ; Wang HY; Wang YF; Peng BG; Zhou Q
Med Oncol; 2015 Mar; 32(3):65. PubMed ID: 25691293
[TBL] [Abstract][Full Text] [Related]
11. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Eun JR; Lee HJ; Moon HJ; Kim TN; Kim JW; Chang JC
Scand J Gastroenterol; 2009; 44(12):1477-86. PubMed ID: 19958061
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
Yeo W; Mok TS; Zee B; Leung TW; Lai PB; Lau WY; Koh J; Mo FK; Yu SC; Chan AT; Hui P; Ma B; Lam KC; Ho WM; Wong HT; Tang A; Johnson PJ
J Natl Cancer Inst; 2005 Oct; 97(20):1532-8. PubMed ID: 16234567
[TBL] [Abstract][Full Text] [Related]
13. Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child.
Okur A; Eser EP; Yilmaz G; Dalgiç A; Akdemir ÜÖ; Oğuz A; Karadeniz C; Akyol G; Demiroğullari B; Boyunağa Ö; Pinarli FG
J Pediatr Hematol Oncol; 2014 Jul; 36(5):e328-32. PubMed ID: 24608073
[TBL] [Abstract][Full Text] [Related]
14. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases.
Katamura Y; Aikata H; Kimura Y; Kawaoka T; Takaki S; Waki K; Hiramatsu A; Kawakami Y; Takahashi S; Ishikawa M; Hieda M; Kakizawa H; Chayama K
J Gastroenterol Hepatol; 2010 Jun; 25(6):1117-22. PubMed ID: 20074168
[TBL] [Abstract][Full Text] [Related]
15. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
Uka K; Aikata H; Takaki S; Miki D; Jeong SC; Hiramatsu A; Kodama H; Shirakawa H; Kawakami Y; Takahashi S; Toyota N; Ito K; Chayama K
Liver Int; 2007 Nov; 27(9):1209-16. PubMed ID: 17919232
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Lenk H; Wiener N; Boese-Landgraf J; Schalhorn A
Semin Oncol; 1992 Apr; 19(2 Suppl 4):57-62. PubMed ID: 1553576
[TBL] [Abstract][Full Text] [Related]
17. [A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil].
Shitara K; Munakata M; Kudo T; Muto O; Okada R; Mitobe S; Sakata Y; Kondo M; Ishii E; Yabu K
Gan To Kagaku Ryoho; 2006 Dec; 33(13):2083-6. PubMed ID: 17197759
[TBL] [Abstract][Full Text] [Related]
18. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches.
Sakon M; Nagano H; Dono K; Nakamori S; Umeshita K; Yamada A; Kawata S; Imai Y; Iijima S; Monden M
Cancer; 2002 Jan; 94(2):435-42. PubMed ID: 11900229
[TBL] [Abstract][Full Text] [Related]
19. [A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil].
Katsuramaki T; Furuhata T; Kimura Y; Yamaguchi K; Ohmura T; Hata F; Mukaiya M; Hirata K
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1801-4. PubMed ID: 12402433
[TBL] [Abstract][Full Text] [Related]
20. Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma.
Uchino K; Obi S; Tateishi R; Sato S; Kanda M; Sato T; Arano T; Enooku K; Goto E; Masuzaki R; Nakagawa H; Asaoka Y; Kondo Y; Yamashiki N; Goto T; Shiina S; Omata M; Yoshida H; Koike K
J Gastroenterol; 2012 Oct; 47(10):1152-9. PubMed ID: 22438097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
